Aripiprazole, a dopamine D 2 receptor partial agonist, is used to treat schizophrenia. Although aripiprazole has been reported to protect non-dopaminergic neurons, its effect on dopaminergic neurons has yet to be investigated. In the present study, we examined whether aripiprazole protected dopaminergic neurons against glutamate-induced cytotoxicity in rat mesencephalic cultures. Pretreatment with aripiprazole protected dopaminergic neurons in a concentration-dependent manner. The neuroprotective effect was not attenuated by sulpiride, a dopamine D 2 receptor antagonist, suggesting that the effect is independent of dopamine D 2 receptors.
Introduction
Aripiprazole, a dopamine D 2 receptor partial agonist, has been used as an atypical antipsychotic [1, 10] . It has been reported that aripiprazole protected against kainic acid-induced striatal lesions by stimulating serotonin 5 -HT 1A receptors [3] , inhibited excessive glutamate release in isolated nerve terminals ( synaptosomes) from the prefrontal cortex [23] and increased glutathione peroxidase activity in the cortex [5] . These reports suggest that aripiprazole is neuroprotective, although its effects on dopaminergic neurons have not been examined.
Glutamate excitotoxicity has been implicated in several neurodegenerative processes, including ischemia and Parkinson 's disease [2] . We previously found that excessive exposure to glutamate caused dopaminergic neuronal death in mesencephalic cultures [9, 20] . We also demonstrated that dopamine D 2 receptor agonists had protective effects against the dopaminergic neurotoxicity [7, 21] . For example, bromocriptine protected mesencephalic neurons by scavenging free radicals via the stimulation of dopamine D 2 receptors [21] , while pramipexole, bromocriptine and 7-OH-DPAT protected dopaminergic neurons by reducing intracellular dopamine content independently of dopamine D 2 receptors [7] . Since aripiprazole also acts as an agonist at presynaptic dopamine D 2 receptors [10] , we examined whether aripiprazole has protective effects against glutamate-induced dopaminergic neurotoxicity in this study. We found that aripiprazole protected dopaminergic neurons against glutamate cytotoxicity in mesencephalic cultures by reducing intracellular dopamine content independently of dopamine D 2 receptors.
Materials and Methods
Aripiprazole was kindly provided by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Sulpiride was purchased from Sigma (St. Louis, MO). Dopamine was obtained from Nacalai Tesque (Kyoto, Japan). GBR12909 was purchased from Tocris Cookson Ltd. (Bristol, UK).
Rat mesencephalic cultures were established according to methods described previously [9] . Briefly, the ventral two-thirds of the mesencephalon was dissected from rat embryos on the 16th day of gestation. The tissues were then chemically and mechanically dissociated into single cell suspensions. Cells were plated onto 0.1% polyethyleneimine-coated plastic coverslips at a density of 1. For the evaluation of neurotoxicity, mesencephalic cultures were exposed to glutamate for 24 h at 9 DIV. Treated cultures were incubated in EMEM containing 10% horse serum without drugs for a further 48 h and fixed for immunocytochemistry.
Following fixation with 4% paraformaldehyde for 30 min, they were incubated with 0.2% Triton X-100 for 10 min. They were then incubated with anti-tyrosine hydroxylase (TH; Chemicon/Millipore, Temecula, CA) antibody for 2 h, with biotinylated secondary antibody for 1.5 h and with avidin -biotinylated horseradish peroxidase complex (Vector Laboratories Inc., Burlingame, CA) for 1.5 h. Finally, they were reacted with diaminobenzidine (Dojindo Laboratories, Kumamoto, Japan) solution for 8 min. For the evaluation of viability, TH-immunoreactive cells were counted in 20 randomly selected fields (858×1287 m 2 /field). Counts were made by an observer blinded to the experimental treatments. The viability of neurons was calculated as a percentage of the number of sham -treated neurons.
Intracellular dopamine content was measured by high performance liquid
chromatography with electrochemical detection ( HPLC-ED) as described previously [9] . Mesencephalic cultures were exposed to drugs at 8 DIV. To measure intracellular dopamine content after treatment with the drugs for 24 h, cells were scraped, centrifuged and resuspended in extraction buffer (200 L) (0.1 N perchloric acid containing 10 mM sodium disulfite and 1 mM EDTA). After sonication, the lysate was centrifuged at 17,000 g for 30 min. The supernatant (50 L) was analyzed by HPLC-ED.
The intracellular dopamine content in sham-treated cells was expressed as 100%. The 
Results
In agreement with our previous report [9] , the exposure of mesencephalic cultures to glutamate (100 M) for 24 h at 9 DIV reduced the viability of dopaminergic neurons. The glutamate-induced dopaminergic neurotoxicity was significantly inhibited by pretreatment with aripiprazole (10 M) for 24 h and/or co-administration of aripiprazole (10 M) with glutamate ( Fig. 1A ). Since the pretreatment by itself was sufficient to protect dopaminergic neurons, it was chosen in subsequent experiments.
Aripiprazole (10-30 M) showed the neuroprotective effect in a concentration-dependent manner (Fig. 1B) , which was not suppressed by sulpiride, a dopamine D 2 receptor antagonist (Fig. 1C) .
We have reported that glutamate -induced dopaminergic neurotoxicity was mediated by intracellular dopamine [ 9] . To investigate the mechanism underlying the neuroprotective effect of aripiprazole, we examined intracellular dopamine content after treatment with aripiprazole for 24 h by HPLC-ED. Aripiprazole reduced intracellular dopamine content in a concentration-dependent manner ( Fig. 2A) . The reduction in intracellular dopamine content by treatment with aripiprazole (30 M) for 24 h was not suppressed by co-administration of sulpiride (30 M) for 24 h, and a significant reduction was observed after treatment with aripiprazole for just 0.5 h ( Fig.   2B and C).
To confirm that the reduction in intracellular dopamine content contribute s to the protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons, dopamine (100 M) was applied for 3 h after 24-hour pretreatment with aripiprazole (30 M), and then the cultures were exposed to glutamate (100 M) in the presence of dopamine (100 M). The neuroprotective effect of aripiprazole against
Discussion
We found that aripiprazole, a dopamine D 2 receptor partial agonist, protected dopaminergic neurons against glutamate cytotoxicity. We previously reported that dopamine D 2 receptor agonists had protective effects against glutamate -induced dopaminergic neurotoxicity dependently or independently of dopamine D 2 receptors [7, 21] . The neuroprotective effect of aripiprazole was not mediated by dopamine D 2 receptors because it was not suppressed by sulpiride.
Endogenous dopamine affects the susceptibility of dopaminergic neurons to
Pael receptor-, rotenone-and -synuclein-induced toxicity [11, 19, 24] . We also demonstrated that glutamate-induced dopaminergic neurotoxicity was mediated by intracellular dopamine [9] . In addition, dopamine D 2 receptor agonists protected dopaminergic neurons against glutamate cytotoxicity by reducing intracellular dopamine content independently of dopamine D 2 receptors [7] . Aripiprazole also reduced intracellular dopamine content in a concentration -dependent manner and the neuroprotective effect of aripiprazole was attenuated by addi tion of dopamine. These results suggest that the protective effect is derived from the reduction in intracellular dopamine content.
The neuroprotective effect was also seen when aripiprazole was administered together with glutamate, although the effect wa s smaller than that when it was administered before glutamate exposure. This result seems reasonable because the treatment with aripiprazole for 0.5 h significantly reduced intracellular dopa mine content but the reduction was smaller than that after treatment for 24 h. We have previously reported that dopamine receptor agonists and antagonists, including aripiprazole, reduced intracellular dopamine content by inhibiting vesicular monoamine uptake in PC12 cells [8, 14] . Thus, it is likely that aripiprazole also reduced intracellular dopamine content by inhibiting vesicular monoamine uptake in mesencephalic cultures, although the mechanisms involved are not examined in the present study. The reduction of intracellular dopamine content by aripiprazole in mesencephalic cultures was observed at lower concentrations than that by pramipexole, bromocriptine and 7-OH-DPAT [7] . It is suggested that aripiprazole inhibits vesicular monoamine uptake more potently than other dopamine receptor agonists.
The protective effect of aripiprazole against glutamate-induced dopaminergic neurotoxicity was not fully suppressed when dopamine was added to the mesencephalic cultures, although intracellular dopamine content was recovered by the addition of dopamine (data not shown). This result suggests that other mechanisms are also involved in the neuroprotection by aripiprazole. It has been reported that the neuroprotective effect of aripiprazole against kainic acid-induced striatal lesions in vivo was related to the activation of serot onin 5-HT 1A receptors [3] . The mechanism underlying neuroprotection by stimulation of serotonin 5-HT 1A receptors is still not fully understood but might involve neuronal hyperpolarization [15, 16] . Since serotonin 5-HT 1A receptors are expressed in dopaminergic neurons of the ventral tegmental area [4] , it is possible that the protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons is also brought by the stimulation of serotonin 5-HT 1A receptors. In fact, it has been reported that 8-OH-DPAT, a serotonin 5-HT 1A receptor agonist, protected against NMDA-induced apoptotic cell death in rat mesencephalic cultures and the neuroprotective effect was inhibited by a 5 -HT 1A antagonist [13] . In addition, it has been reported that aripiprazole increased brain-derived neurotrophic factor (BDNF) levels and glutathione peroxidase activity [5, 17] . Therefore, it is possible that aripiprazole protects dopaminergic neurons against glutamate cytotoxicity not only by reducing intracellular dopamin e content but also by stimulating serotonin 5-HT 1A receptors and increasing levels of neuroprotective factors.
However, further experiments will be required to examine whether serotonin 5-HT 1A receptors and these factors contribute to the protective effect of aripiprazole on dopaminergic neurons.
Some reports suggest that aripiprazole may be useful for reducing psychosis and improving mood and cognition in patients with Parkinson's disease [6, 12, 22] . As glutamate cytotoxicity has been suggested to contribute to the continued degeneration of dopaminergic neurons in the progression of Parkinson 's disease [18] , aripiprazole may have the potential to inhibit dopaminergic neuronal degeneration in Parkinson 's disease.
In conclusion, aripiprazole protect ed dopaminergic neurons against glutamate cytotoxicity by reducing intracellular dopamine content. Our results provide a novel insight into the neuroprotective effect of aripiprazole on dopaminergic neurons. 
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